This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

West To Co-present Research Findings On Understanding The Patient Journey Through The Phases Of A Chronic Disease

EXTON, Pa., Nov. 1, 2013 /PRNewswire/ --  West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, has completed primary user research with its partner, Insight Product Development, aimed at understanding the needs of patients, caregivers and clinicians in the field of injectable therapies for chronic diseases. West will co-present a poster summarizing the findings at the Parenteral Drug Association (PDA) conference on "The Universe of Prefilled Syringes and Injection Devices" in Basel, Switzerland November 5-6.

Chris Evans, Director of Innovation at West, and Craig Scherer, Senior Partner of Insight, will present at 10:45 a.m. on November 5 and during session breaks throughout both days of the conference.

With the increase in chronic conditions such as diabetes and autoimmune diseases (such as rheumatoid arthritis and multiple sclerosis) it is becoming more critical to provide safe and effective drug delivery systems that can be used by the patient for self-administration in the home environment. West provides a number of solutions to support the packaging and delivery of these conditions, and realizes the importance of ensuring a deep understanding of patients' needs. This is essential to ensure that systems are provided that optimize patient experience and improve outcomes through the patient's journey from initial diagnosis to a point of being in control of their treatment.

"Effective drug delivery is no longer just about the drug molecule," said Graham Reynolds, Vice President of Marketing and Innovation at West. "We recognize that a medicine can be truly effective only if it is contained and delivered safely, and if the patient maintains adherence to the required regimen. This can be achieved by providing a delivery system that enables effective delivery, and is designed with a recognition and understanding of the patient's emotional and physical state at various stages of the journey."

West has a seven-year relationship with Insight Product Development, a healthcare-centric product development consultancy. "Being able to identify and frame the needs of the users as they relate to their delivery device is critical for pharmaceutical companies to support the patient beyond the drug," said Craig Scherer, Senior Partner of Insight. "This process is critical to innovating differentiated devices that help drive adoption and adherence, resulting in better outcomes for the patient and greater success for pharmaceutical companies."

The paper to be presented at the PDA conference will highlight the transition from initial diagnosis, often creating a feeling of denial and depression. In this stage of the journey, the patient may make comments such as, "All of a sudden it's there, and you didn't want it or plan for it." As the journey progresses, the patient may feel in control of the treatment, and make comments such as, "It's a marathon not a sprint" and "I'm always working on being better." West will use the study results to work with its pharmaceutical partners to help improve patient outcomes.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,025.65 -13.84 -0.08%
S&P 500 1,992.18 -0.19 -0.01%
NASDAQ 4,545.1080 +13.0040 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs